Janux Therapeutics Inc (OQ:JANX)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 10955 Vista Sorrento Parkway, Suite 200
Tel: N/A
Website: https://www.januxrx.com
IR: See website
Key People
Jay B. Lichter
Chairman of the Board
David Campbell
President, Chief Executive Officer, Founder, Director
Tommy Diraimondo
Co-Founder, Chief Scientific Officer
Tighe Reardon
Acting Chief Financial Officer
Charles Winter
Chief Technology Officer
Andy Meyer
Chief Business Officer
Byron Robinson
Chief Strategy Officer
Business Overview
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Financial Overview
For the three months ended 31 March 2024, Janux Therapeutics Inc revenues decreased 39% to $1.3M. Net loss decreased 15% to $14.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Interest income increase of 91% to $5.4M (income), Research and development - Balancing va decrease of 12% to $11.9M (expense).
Employees: 64 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $1,540M as of Mar 31, 2024
Annual revenue (TTM): $7.29M as of Mar 31, 2024
EBITDA (TTM): -$70.83M as of Mar 31, 2024
Net annual income (TTM): -$55.59M as of Mar 31, 2024
Free cash flow (TTM): -$53.26M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 51,850,667 as of Apr 29, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.